First Randomized Trial Of Remdesivir Suggests Antiviral Drug Isn’t Associated With Significant Clinical Benefits, More Research Needed

Treatment with the antiviral drug remdesivir does not speed recovery from COVID-19 compared with placebo in hospitalised patients who are critically ill, according to the first randomised trial of its kind involving 237 adults (aged 18 and older) from ten hospitals in Wuhan, China, published in The Lancet.

Although their...